Meeting Coverage
ACR 2021 Features Sessions
Nov 2, 2021
Keynote Lecture: The Covidization of Rheumatology: What Will or Won’t Change Beyond the COVID-19...
Read MoreASN Kidney Week Learning Pathways
Nov 2, 2021
The following learning pathways will help attendees locate sessions in their area of interest: Acute Kidney Injury Bone and Mineral Metabolism Cell and Transport Physiology Chronic Kidney Disease Development and Pediatrics...
Read MoreASN Kidney Week 2021 Abstracts & Info on What’s New
Nov 2, 2021
Browse or search Kidney Week 2021 Abstracts by type, category, presentation date, author first or last name, or keyword. Find out what’s new this year at Kidney Week 2021.
Read MoreASN Kidney Week 2021 Program, FAQs & Meeting Overview
Nov 2, 2021
With increasing uncertainties around variants of the COVID-19 virus, ASN has canceled plans for the in-person component of ASN Kidney Week 2021 in San Diego, CA, and chosen a fully virtual experience for attendees. Access the...
Read MoreACR Convergence 2021 Accepted Abstracts
Nov 2, 2021
Accepted abstracts will be published in an online supplement of the Arthritis & Rheumatology journal. Accepted and late-breaking abstracts are also available on the ACR Convergence Meeting Abstracts website. Check out...
Read MoreACR Convergence 2021 Preview & Program
Nov 2, 2021
The ACR’s first-rate education program showcases cutting-edge and timely topics in rheumatology, as well as the prevention, diagnosis, and treatment of rheumatic diseases and related comorbid conditions. ACR Convergence...
Read MoreConference Highlights: ASTRO 2021
Oct 29, 2021
New research was presented at ASTRO 2021, the American Society for Radiation Oncology Annual...
Read MoreDialysis-Dependent Patients With Gout Have High Comorbidity Burden
Oct 28, 2021
Using 2017 USRDS data, researchers identified dialysis patients aged 18 and older with Medicare as the primary payer. Baseline characteristics and comorbid conditions for patients with gout who were dialysis-dependent were...
Read MorePegloticase With Immunomodulation Co-Therapy Produces Favorable Response
Oct 28, 2021
Prior research has shown that pegloticase therapy for uncontrolled gout does not require renal adjustments and is effective across all stages of CKD. Pegloticase with immunomodulating (IMM) co-therapy demonstrated an increased...
Read MoreSerum Bicarbonate Not Linked With Gout in Patients With Advanced CKD
Oct 28, 2021
Since patients with CKD are at increased risk for gout and alkalinization solubilizes uric acid, investigators sought to determine if baseline bicarbonate or change in bicarbonate was an independent predictor of incident gout in...
Read MoreAmong Patients With CKD, Gout Is Common & Impactful
Oct 28, 2021
With evidence that gout highly impacts patients with advanced CKD, through increased healthcare utilization and higher cardiovascular and bone/joint comorbidity and patients with uncontrolled gout (UCG) show to have an even...
Read MoreInitial Pegloticase Serum Levels Predict Responsiveness in Patients With Chronic Gout
Oct 28, 2021
In patients with chronic refractory gout whose serum urate (SU) was not maintained at ≤6 mg/dL, adding an additional tolerizing dose of pegloticase between the first and second biweekly administrations showed an overall response...
Read MorePegloticase Treatment Significantly Decreased BP in Patients With Chronic Gout
Oct 28, 2021
Serum urate (SU) responders to pegloticase experienced significant reductions in mean arterial pressure (MAP) that were independent of changes in renal function, according to prior randomized clinical trials (RCTs). To determine...
Read MoreEfficacy & Safety Shown in Pegloticase With Concomitant IMM
Oct 28, 2021
Small clinical trials have shown that concomitant immunomodulatory (IMM) drug use improves pegloticase persistence in the treatment of gout. However, real-world evidence has been lacking. Therefore, researchers evaluated...
Read MoreTreat-to-Target Lowers MACE in Patients With Gout
Oct 28, 2021
In a large cohort of older patients with gout who started urate-lowering therapy (ULT), researchers observed a decrease in the rate in major adverse cardiovascular events (MACE) with a treat-to-target (TTT) strategy compared...
Read MoreECTRIMS 2021: MRI & Clinical Features Discriminate Between MOGAD, AQP4-NMOSD & RR-MS
Oct 25, 2021
Magnetic resonance imaging (MRI) and clinical characteristics could differentiate between...
Read More